Mirum Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
MIRM$93.18-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net loss | $(163,415) | $(135,665) | $(83,988) |
| Other comprehensive gain (loss): | |||
| Unrealized gain (loss) on available-for-sale investments | 230 | (194) | (117) |
| Cumulative translation adjustments | 1,631 | 12 | (1) |
| Comprehensive loss | $(161,554) | $(135,847) | $(84,106) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.